Cited by

• Role of antibodies to murine leukemia virus p15E transmembrane protein in immunotherapy against AKR leukemia: a model for studies in human acquired immunodeficiency syndrome.

  Thiel HJ, Schwarz H, Fischinger P, Bolognesi D, Schäfer W. Thiel HJ, et al. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5893-7. doi: 10.1073/pnas.84.16.5893. Proc Natl Acad Sci U S A. 1987. PMID: 3039513 Free PMC article.
• The immune response of (C57BL/6 X C3H)F1 mice to the endogenous AKR-MuLV.

  Ihle JN, Lee JC. Ihle JN, et al. Med Microbiol Immunol. 1977;164(1-3):207-16. doi: 10.1007/BF02121315. Med Microbiol Immunol. 1977. PMID: 202851 No abstract available.
• Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies.

  Nara PL, Robey WG, Pyle SW, Hatch WC, Dunlop NM, Bess JW Jr, Kelliher JC, Arthur LO, Fischinger PJ. Nara PL, et al. J Virol. 1988 Aug;62(8):2622-8. doi: 10.1128/JVI.62.8.2622-2628.1988. J Virol. 1988. PMID: 3392769 Free PMC article.
• Feline oncornavirus-associated cell-membrane antigen (FOCMA): distinction between FOCMA and the major virion glycoprotein.

  Stephenson JR, Essex M, Hino S, Hardy WD Jr, Aaronson SA. Stephenson JR, et al. Proc Natl Acad Sci U S A. 1977 Mar;74(3):1219-23. doi: 10.1073/pnas.74.3.1219. Proc Natl Acad Sci U S A. 1977. PMID: 191832 Free PMC article.
• Immunization of mice with syngeneic Moloney lymphoma cells induces separate antibodies against virion envelope glycoprotein and virus-induced cell surface antigens.

  Fenyo EM, Yefenof E, Klein E, Klein G. Fenyo EM, et al. J Exp Med. 1977 Dec 1;146(6):1521-33. doi: 10.1084/jem.146.6.1521. J Exp Med. 1977. PMID: 925612 Free PMC article.